Educational Report: Kelly CRISPR & Gene Editing Technology ETF (XDNA)

The Kelly CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund designed to invest in companies involved in CRISPR and gene editing technologies. Based on the supplied data, this ETF focuses on growth in the biotech sector rather than providing regular cash income to investors.

What the Numbers Show

As of October 9, 2026, the share price of XDNA is $7.38. The estimated price from roughly one year ago was also $7.38, resulting in a one-year price return of 0%. The year-to-date price return is also 0%.

Looking further back, the three-year price return is approximately 4.09%. Because there were no distributions during this time, the three-year total return is also 4.09%.

Income and Distribution Explanation

XDNA does not currently provide a distribution yield. The data shows 0% for the distribution yield and zero payouts over the last 12 months. The distribution frequency is listed as "No distributions detected."

For new investors, it is important to know that some ETFs pay regular cash (dividends), while others, like this one, do not. Investors in XDNA cannot rely on this fund for regular cash income.

Price and NAV Erosion Explanation

"NAV erosion" happens when the net asset value of a fund's holdings declines over time. The supplied data is sufficient to evaluate price erosion, but it does not include enough historical NAV-per-share data to confirm or rule out NAV erosion.

Regarding price-based evidence, XDNA has an erosion-risk score of 94, which is labeled as "Stable / sideways" with "good" severity. Additionally, the severe erosion-risk flag is false, meaning the fund has not triggered the specific warnings associated with substantial price deterioration.

Pros

• Price Stability: The erosion-risk score suggests the price has been stable or moving sideways.

• Positive Long-Term Trend: The fund shows a positive price return over a three-year period (4.09%).

Cons

• No Income: There are no distributions or yields for investors seeking cash flow.

• Flat Recent Performance: The one-year and year-to-date price returns are both 0%.

• Limited Data: No top holdings were supplied in the data to show exactly which companies the fund owns.

Beginner Takeaway

XDNA is a specialized ETF focusing on gene-editing technology. It is not an income-generating fund. While its recent one-year performance has been flat, its three-year history is slightly positive, and its erosion-risk score indicates a stable price trend.